BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zitvogel L, Pitt JM, Daillère R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer 2016;16:759-73. [PMID: 27687979 DOI: 10.1038/nrc.2016.91] [Cited by in Crossref: 162] [Cited by in F6Publishing: 147] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17:271-285. [PMID: 28303904 DOI: 10.1038/nrc.2017.13] [Cited by in Crossref: 370] [Cited by in F6Publishing: 348] [Article Influence: 74.0] [Reference Citation Analysis]
2 Zhao X, Li L, Starr TK, Subramanian S. Tumor location impacts immune response in mouse models of colon cancer. Oncotarget 2017;8:54775-87. [PMID: 28903381 DOI: 10.18632/oncotarget.18423] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
3 Bailey KL, Carlson MA. Porcine Models of Pancreatic Cancer. Front Oncol 2019;9:144. [PMID: 30915276 DOI: 10.3389/fonc.2019.00144] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
4 Li J, Van Valkenburgh J, Hong X, Conti PS, Zhang X, Chen K. Small molecules as theranostic agents in cancer immunology. Theranostics 2019;9:7849-71. [PMID: 31695804 DOI: 10.7150/thno.37218] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
5 Merlot AM, Kalinowski DS, Kovacevic Z, Jansson PJ, Sahni S, Huang ML, Lane DJ, Lok H, Richardson DR. Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents. CMC 2019;26:302-22. [DOI: 10.2174/0929867324666170705120809] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
6 Meraz IM, Majidi M, Meng F, Shao R, Ha MJ, Neri S, Fang B, Lin SH, Tinkey PT, Shpall EJ, Morris J, Roth JA. An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. Cancer Immunol Res 2019;7:1267-79. [PMID: 31186248 DOI: 10.1158/2326-6066.CIR-18-0874] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
7 Ding X, Zhao T, Lee CC, Yan C, Du H. Lysosomal Acid Lipase Deficiency Controls T- and B-Regulatory Cell Homeostasis in the Lymph Nodes of Mice with Human Cancer Xenotransplants. Am J Pathol 2021;191:353-67. [PMID: 33159889 DOI: 10.1016/j.ajpath.2020.10.007] [Reference Citation Analysis]
8 Taylor MA, Hughes AM, Walton J, Coenen-Stass AML, Magiera L, Mooney L, Bell S, Staniszewska AD, Sandin LC, Barry ST, Watkins A, Carnevalli LS, Hardaker EL. Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery. J Immunother Cancer 2019;7:328. [PMID: 31779705 DOI: 10.1186/s40425-019-0794-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
9 Petroni G, Buqué A, Yamazaki T, Bloy N, Liberto MD, Chen-Kiang S, Formenti SC, Galluzzi L. Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer. Clin Cancer Res 2021;27:1855-63. [PMID: 33495311 DOI: 10.1158/1078-0432.CCR-20-3871] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Day D, Monjazeb AM, Sharon E, Ivy SP, Rubin EH, Rosner GL, Butler MO. From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. Clin Cancer Res 2017;23:4980-91. [PMID: 28864726 DOI: 10.1158/1078-0432.CCR-16-3064] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
11 Li P, Rozich N, Wang J, Wang J, Xu Y, Herbst B, Yu R, Muth S, Niu N, Li K, Funes V, Gai J, Osipov A, Edil BH, Wolfgang CL, Lei M, Liang T, Zheng L. Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215722] [Reference Citation Analysis]
12 Jackson SJ, Thomas GJ. Human tissue models in cancer research: looking beyond the mouse. Dis Model Mech 2017;10:939-42. [PMID: 28768734 DOI: 10.1242/dmm.031260] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
13 Saglam-metiner P, Gulce-iz S, Biray-avci C. Bioengineering-inspired three-dimensional culture systems: Organoids to create tumor microenvironment. Gene 2019;686:203-12. [DOI: 10.1016/j.gene.2018.11.058] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
14 Li J, Zhang P, Zhou M, Liu C, Huang Y, Li L. Trauma-Responsive Scaffold Synchronizing Oncolysis Immunization and Inflammation Alleviation for Post-Operative Suppression of Cancer Metastasis. ACS Nano 2022. [PMID: 35344338 DOI: 10.1021/acsnano.1c11562] [Reference Citation Analysis]
15 Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer 2019;7:131. [PMID: 31113486 DOI: 10.1186/s40425-019-0602-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 12.0] [Reference Citation Analysis]
16 Miao YR, Xia M, Luo M, Luo T, Yang M, Guo AY. ImmuCellAI-mouse: a tool for comprehensive prediction of mouse immune cell abundance and immune microenvironment depiction. Bioinformatics 2021:btab711. [PMID: 34636837 DOI: 10.1093/bioinformatics/btab711] [Reference Citation Analysis]
17 Paul CD, Devine A, Bishop K, Xu Q, Wulftange WJ, Burr H, Daly KM, Lewis C, Green DS, Staunton JR, Choksi S, Liu ZG, Sood R, Tanner K. Human macrophages survive and adopt activated genotypes in living zebrafish. Sci Rep 2019;9:1759. [PMID: 30741975 DOI: 10.1038/s41598-018-38186-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
18 Boyero L, Sánchez-Gastaldo A, Alonso M, Noguera-Uclés JF, Molina-Pinelo S, Bernabé-Caro R. Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy. Cancers (Basel) 2020;12:E3729. [PMID: 33322522 DOI: 10.3390/cancers12123729] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
19 Fucikova J, Palova-Jelinkova L, Klapp V, Holicek P, Lanickova T, Kasikova L, Drozenova J, Cibula D, Álvarez-Abril B, García-Martínez E, Spisek R, Galluzzi L. Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. Trends Cancer 2022:S2405-8033(22)00017-6. [PMID: 35181272 DOI: 10.1016/j.trecan.2022.01.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Vilariño M, García-Sanmartín J, Ochoa-Callejero L, López-Rodríguez A, Blanco-Urgoiti J, Martínez A. Macrocybin, a Natural Mushroom Triglyceride, Reduces Tumor Growth In Vitro and In Vivo through Caveolin-Mediated Interference with the Actin Cytoskeleton. Molecules 2020;25:E6010. [PMID: 33353176 DOI: 10.3390/molecules25246010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Li QX, Feuer G, Ouyang X, An X. Experimental animal modeling for immuno-oncology. Pharmacol Ther 2017;173:34-46. [PMID: 28167217 DOI: 10.1016/j.pharmthera.2017.02.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
22 Yofe I, Dahan R, Amit I. Single-cell genomic approaches for developing the next generation of immunotherapies. Nat Med 2020;26:171-7. [PMID: 32015555 DOI: 10.1038/s41591-019-0736-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
23 Alisjahbana A, Mohammad I, Gao Y, Evren E, Ringqvist E, Willinger T. Human macrophages and innate lymphoid cells: Tissue-resident innate immunity in humanized mice. Biochem Pharmacol 2020;174:113672. [PMID: 31634458 DOI: 10.1016/j.bcp.2019.113672] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
24 Morton JJ, Alzofon N, Jimeno A. The humanized mouse: Emerging translational potential. Mol Carcinog 2020;59:830-8. [PMID: 32275343 DOI: 10.1002/mc.23195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
25 Nakashima H, Alayo QA, Penaloza-MacMaster P, Freeman GJ, Kuchroo VK, Reardon DA, Fernandez S, Caligiuri M, Chiocca EA. Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 2018;8:208. [PMID: 29317703 DOI: 10.1038/s41598-017-18540-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
26 Hußtegge M, Hoang NA, Rebstock J, Monecke A, Gockel I, Weimann A, Schumacher G, Bechmann I, Lordick F, Kallendrusch S, Körfer J. PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma. Oncoimmunology 2021;10:1960729. [PMID: 34434611 DOI: 10.1080/2162402X.2021.1960729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Leung CS. Analysis of ROR1 Protein Expression in Mice with Reconstituted Human Immune System Components. J Immunol Res 2018;2018:2480931. [PMID: 29850623 DOI: 10.1155/2018/2480931] [Reference Citation Analysis]
28 Liu WN, Fong SY, Tan WWS, Tan SY, Liu M, Cheng JY, Lim S, Suteja L, Huang EK, Chan JKY, Iyer NG, Yeong JPS, Lim DW, Chen Q. Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy. Cancers (Basel) 2020;12:E1025. [PMID: 32331230 DOI: 10.3390/cancers12041025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
29 Guzzeloni V, Veschini L, Pedica F, Ferrero E, Ferrarini M. 3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations. Antibodies 2022;11:46. [DOI: 10.3390/antib11030046] [Reference Citation Analysis]
30 Ochoa de Olza M, Oliva M, Hierro C, Matos I, Martin-Liberal J, Garralda E. Early-drug development in the era of immuno-oncology: are we ready to face the challenges? Ann Oncol 2018;29:1727-40. [PMID: 29945232 DOI: 10.1093/annonc/mdy225] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
31 Huck BR, Kötzner L, Urbahns K. Small Molecules Drive Big Improvements in Immuno-Oncology Therapies. Angew Chem Int Ed Engl 2018;57:4412-28. [PMID: 28971564 DOI: 10.1002/anie.201707816] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 16.3] [Reference Citation Analysis]
32 Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267-1284. [PMID: 30275043 DOI: 10.1101/gad.314617.118] [Cited by in Crossref: 419] [Cited by in F6Publishing: 401] [Article Influence: 104.8] [Reference Citation Analysis]
33 Möhwald M, Pinnapireddy SR, Wonnenberg B, Pourasghar M, Jurisic M, Jung A, Fink-Straube C, Tschernig T, Bakowsky U, Schneider M. Aspherical, Nanostructured Microparticles for Targeted Gene Delivery to Alveolar Macrophages. Adv Healthc Mater 2017;6. [PMID: 28726349 DOI: 10.1002/adhm.201700478] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
34 Baert T, Garg AD, Agostinis P, Vergote I, Coosemans A. Orientation of Preclinical Research in Ovarian Cancer. Int J Gynecol Cancer 2017;27:1579-86. [PMID: 28945211 DOI: 10.1097/IGC.0000000000001053] [Reference Citation Analysis]
35 Horowitz NB, Mohammad I, Moreno-Nieves UY, Koliesnik I, Tran Q, Sunwoo JB. Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies. Front Immunol 2021;12:648580. [PMID: 33968039 DOI: 10.3389/fimmu.2021.648580] [Reference Citation Analysis]
36 Pedersen SF, Novak I, Alves F, Schwab A, Pardo LA. Alternating pH landscapes shape epithelial cancer initiation and progression: Focus on pancreatic cancer. BioEssays 2017;39:1600253. [DOI: 10.1002/bies.201600253] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
37 Ni S, Chen R, Hu K. Experimental murine models of brainstem gliomas. Drug Discov Today 2021:S1359-6446(21)00567-5. [PMID: 34954326 DOI: 10.1016/j.drudis.2021.12.016] [Reference Citation Analysis]
38 Gengenbacher N, Singhal M, Augustin HG. Preclinical mouse solid tumour models: status quo, challenges and perspectives. Nat Rev Cancer 2017;17:751-65. [PMID: 29077691 DOI: 10.1038/nrc.2017.92] [Cited by in Crossref: 125] [Cited by in F6Publishing: 110] [Article Influence: 25.0] [Reference Citation Analysis]
39 Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, Villacorta-Martin C, Singhi AD, Moghe A, von Felden J, Tal Grinspan L, Wang S, Kamphorst AO, Monga SP, Brown BD, Villanueva A, Llovet JM, Merad M, Lujambio A. β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discov 2019;9:1124-41. [PMID: 31186238 DOI: 10.1158/2159-8290.CD-19-0074] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Sica V, Bravo-San Pedro JM, Stoll G, Kroemer G. Oxidative phosphorylation as a potential therapeutic target for cancer therapy. Int J Cancer 2020;146:10-7. [PMID: 31396957 DOI: 10.1002/ijc.32616] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
41 Gahete MD, Jimenez-Vacas JM, Alors-Perez E, Herrero-Aguayo V, Fuentes-Fayos AC, Pedraza-Arevalo S, Castaño JP, Luque RM. Mouse models in endocrine tumors. J Endocrinol 2018:JOE-18-0571. [PMID: 30475226 DOI: 10.1530/JOE-18-0571] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
42 Abreu TR, Biscaia M, Gonçalves N, Fonseca NA, Moreira JN. In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles. Adv Exp Med Biol 2021;1295:271-99. [PMID: 33543464 DOI: 10.1007/978-3-030-58174-9_12] [Reference Citation Analysis]
43 Kramer MG, Masner M, Ferreira FA, Hoffman RM. Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions. Front Microbiol 2018;9:16. [PMID: 29472896 DOI: 10.3389/fmicb.2018.00016] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 11.0] [Reference Citation Analysis]
44 Park J, Tu H, Marjanovic M, Boppart SA. Label-Free Multimodal Multiphoton Intravital Imaging. Adv Exp Med Biol 2021;3233:127-46. [PMID: 34053026 DOI: 10.1007/978-981-15-7627-0_7] [Reference Citation Analysis]
45 Musella M, Galassi C, Manduca N, Sistigu A. The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation. Biology (Basel) 2021;10:856. [PMID: 34571733 DOI: 10.3390/biology10090856] [Reference Citation Analysis]
46 Ma X, Riaz N, Samstein RM, Lee M, Makarov V, Valero C, Chowell D, Kuo F, Hoen D, Fitzgerald CWR, Jiang H, Alektiar J, Alban TJ, Juric I, Parthasarathy PB, Zhao Y, Sabio EY, Verma R, Srivastava RM, Vuong L, Yang W, Zhang X, Wang J, Chu LK, Wang SL, Kelly DW, Pei X, Chen J, Yaeger R, Zamarin D, Zehir A, Gönen M, Morris LGT, Chan TA. Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. Nat Genet 2022;54:996-1012. [PMID: 35817971 DOI: 10.1038/s41588-022-01108-w] [Reference Citation Analysis]
47 Endharti AT, Permana S. Extract from mango mistletoes Dendrophthoe pentandra ameliorates TNBS-induced colitis by regulating CD4+ T cells in mesenteric lymph nodes. BMC Complement Altern Med 2017;17:468. [PMID: 28946886 DOI: 10.1186/s12906-017-1973-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
48 Igarashi K, Kawaguchi K, Li S, Han Q, Tan Y, Murakami T, Kiyuna T, Miyake K, Miyake M, Singh AS, Eckardt MA, Nelson SD, Russell TA, Dry SM, Li Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Tsuchiya H, Singh SR, Eilber FC, Hoffman RM. Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. Cancer Letters 2018;417:168-73. [DOI: 10.1016/j.canlet.2017.12.028] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
49 Hensel JA, Khattar V, Ashton R, Ponnazhagan S. Characterization of immune cell subtypes in three commonly used mouse strains reveals gender and strain-specific variations. Lab Invest 2019;99:93-106. [PMID: 30353130 DOI: 10.1038/s41374-018-0137-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
50 Daguenet E, Louati S, Wozny AS, Vial N, Gras M, Guy JB, Vallard A, Rodriguez-Lafrasse C, Magné N. Radiation-induced bystander and abscopal effects: important lessons from preclinical models. Br J Cancer 2020;123:339-48. [PMID: 32581341 DOI: 10.1038/s41416-020-0942-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
51 Mondal P, Bailey KL, Cartwright SB, Band V, Carlson MA. Large Animal Models of Breast Cancer. Front Oncol 2022;12:788038. [DOI: 10.3389/fonc.2022.788038] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Shue YT, Lim JS, Sage J. Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models. Transl Lung Cancer Res 2018;7:21-31. [PMID: 29535910 DOI: 10.21037/tlcr.2018.01.15] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
53 Wernitznig D, Kiakos K, Del Favero G, Harrer N, Machat H, Osswald A, Jakupec MA, Wernitznig A, Sommergruber W, Keppler BK. First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro. Metallomics 2019;11:1044-8. [DOI: 10.1039/c9mt00051h] [Cited by in Crossref: 47] [Cited by in F6Publishing: 19] [Article Influence: 15.7] [Reference Citation Analysis]
54 Porporato PE, Filigheddu N, Pedro JMB, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Res 2018;28:265-80. [PMID: 29219147 DOI: 10.1038/cr.2017.155] [Cited by in Crossref: 333] [Cited by in F6Publishing: 330] [Article Influence: 66.6] [Reference Citation Analysis]
55 Zhou Z, Zhu J, Jiang M, Sang L, Hao K, He H. The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development. Pharmaceutics 2021;13:704. [PMID: 34065907 DOI: 10.3390/pharmaceutics13050704] [Reference Citation Analysis]
56 Roque-Lima B, Roque CCTA, Begnami MD, Peresi P, Lima ENP, Mello CAL, Coimbra FJ, Chojniak R, Goss Santos T. Development of patient-derived orthotopic xenografts from metastatic colorectal cancer in nude mice. J Drug Target 2019;27:943-9. [PMID: 30088428 DOI: 10.1080/1061186X.2018.1509983] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Xu D, Wang L, Wieczorek K, Zhang Y, Wang Z, Wang J, Xu B, Singh PK, Wang Y, Zhang X, Wu Y, Smith GJ, Attwood K, Zhang Y, Goodrich DW, Li Q. Single-Cell Analyses of a Novel Mouse Urothelial Carcinoma Model Reveal a Role of Tumor-Associated Macrophages in Response to Anti-PD-1 Therapy. Cancers (Basel) 2022;14:2511. [PMID: 35626115 DOI: 10.3390/cancers14102511] [Reference Citation Analysis]
58 Balasubramanian B, Venkatraman S, Myint KZ, Janvilisri T, Wongprasert K, Kumkate S, Bates DO, Tohtong R. Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma. Pharmaceuticals (Basel) 2021;14:51. [PMID: 33440754 DOI: 10.3390/ph14010051] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Sampetrean O, Saya H. Modeling phenotypes of malignant gliomas. Cancer Sci 2018;109:6-14. [PMID: 28796931 DOI: 10.1111/cas.13351] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
60 Bi Y, Wang Q, Yang Y, Wang Q, Zhang K, Zhang X, Cho WC, Shu Z, Li J, Liu L, Si C, Hong F. Establishment of a Human Gastric Cancer Xenograft Model in Immunocompetent Mice Using the Microcarrier-6. Biomed Res Int 2020;2020:1893434. [PMID: 32337226 DOI: 10.1155/2020/1893434] [Reference Citation Analysis]
61 Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol 2020;17:725-41. [PMID: 32760014 DOI: 10.1038/s41571-020-0413-z] [Cited by in Crossref: 74] [Cited by in F6Publishing: 88] [Article Influence: 37.0] [Reference Citation Analysis]
62 Fagerland ST, Berg S, Hill DK, Snipstad S, Sulheim E, Hyldbakk A, Kim J, Davies CL. Ultrasound-Mediated Delivery of Chemotherapy into the Transgenic Adenocarcinoma of the Mouse Prostate Model. Ultrasound Med Biol 2020;46:3032-45. [PMID: 32800470 DOI: 10.1016/j.ultrasmedbio.2020.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J, Spisek R, Demaria S, Formenti SC, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immune checkpoint blockers for cancer therapy. Oncoimmunology 2017;6:e1373237. [PMID: 29147629 DOI: 10.1080/2162402X.2017.1373237] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
64 Boshuizen J, Peeper DS. Rational Cancer Treatment Combinations: An Urgent Clinical Need. Molecular Cell 2020;78:1002-18. [DOI: 10.1016/j.molcel.2020.05.031] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
65 Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 2017;14:717-34. [PMID: 28741618 DOI: 10.1038/nrclinonc.2017.101] [Cited by in Crossref: 683] [Cited by in F6Publishing: 675] [Article Influence: 136.6] [Reference Citation Analysis]
66 Bresnahan E, Lindblad KE, Ruiz de Galarreta M, Lujambio A. Mouse Models of Oncoimmunology in Hepatocellular Carcinoma. Clin Cancer Res 2020;26:5276-86. [PMID: 32327473 DOI: 10.1158/1078-0432.CCR-19-2923] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
67 Ceppi F, Beck-Popovic M, Bourquin JP, Renella R. Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. Eur J Pediatr 2017;176:1163-72. [PMID: 28803259 DOI: 10.1007/s00431-017-2982-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
68 Fournel L, Wu Z, Stadler N, Damotte D, Lococo F, Boulle G, Ségal-Bendirdjian E, Bobbio A, Icard P, Trédaniel J, Alifano M, Forgez P. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. Cancer Lett 2019;464:5-14. [PMID: 31404614 DOI: 10.1016/j.canlet.2019.08.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
69 Bule P, Aguiar SI, Aires-Da-Silva F, Dias JNR. Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy. Int J Mol Sci 2021;22:9804. [PMID: 34575965 DOI: 10.3390/ijms22189804] [Reference Citation Analysis]
70 Stribbling SM, Ryan AJ. The cell-line-derived subcutaneous tumor model in preclinical cancer research. Nat Protoc 2022. [PMID: 35859135 DOI: 10.1038/s41596-022-00709-3] [Reference Citation Analysis]
71 Golombek SK, May JN, Theek B, Appold L, Drude N, Kiessling F, Lammers T. Tumor targeting via EPR: Strategies to enhance patient responses. Adv Drug Deliv Rev 2018;130:17-38. [PMID: 30009886 DOI: 10.1016/j.addr.2018.07.007] [Cited by in Crossref: 606] [Cited by in F6Publishing: 522] [Article Influence: 151.5] [Reference Citation Analysis]
72 Yuan Y, Wang Z, Yang R, Qian T, Zhou Q. Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination. Eur J Med Chem 2019;171:255-64. [PMID: 30925340 DOI: 10.1016/j.ejmech.2019.03.051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
73 Schetters STT, Rodriguez E, Kruijssen LJW, Crommentuijn MHW, Boon L, Van den Bossche J, Den Haan JMM, Van Kooyk Y. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy. J Immunother Cancer 2020;8:e000588. [PMID: 32690667 DOI: 10.1136/jitc-2020-000588] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
74 Bailey KL, Cartwright SB, Patel NS, Remmers N, Lazenby AJ, Hollingsworth MA, Carlson MA. Porcine pancreatic ductal epithelial cells transformed with KRASG12D and SV40T are tumorigenic. Sci Rep 2021;11:13436. [PMID: 34183736 DOI: 10.1038/s41598-021-92852-2] [Reference Citation Analysis]
75 Huang M, Yang J, Li P, Chen Y. Embryo-Engineered Nonhuman Primate Models: Progress and Gap to Translational Medicine. Research (Wash D C) 2021;2021:9898769. [PMID: 34549187 DOI: 10.34133/2021/9898769] [Reference Citation Analysis]
76 Cox MC, Mendes R, Silva F, Mendes TF, Zelaya-Lazo A, Halwachs K, Purkal JJ, Isidro IA, Félix A, Boghaert ER, Brito C. Application of LDH assay for therapeutic efficacy evaluation of ex vivo tumor models. Sci Rep 2021;11:18571. [PMID: 34535719 DOI: 10.1038/s41598-021-97894-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 2018;175:313-326. [PMID: 30290139 DOI: 10.1016/j.cell.2018.09.035] [Cited by in Crossref: 390] [Cited by in F6Publishing: 399] [Article Influence: 130.0] [Reference Citation Analysis]
78 Villacorta-Martin C, Craig AJ, Villanueva A. Divergent evolutionary trajectories in transplanted tumor models. Nat Genet 2017;49:1565-6. [PMID: 29074950 DOI: 10.1038/ng.3983] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
79 Spyridopoulou K, Aindelis G, Lampri E, Giorgalli M, Lamprianidou E, Kotsianidis I, Tsingotjidou A, Pappa A, Kalogirou O, Chlichlia K. Improving the Subcutaneous Mouse Tumor Model by Effective Manipulation of Magnetic Nanoparticles-Treated Implanted Cancer Cells. Ann Biomed Eng 2018;46:1975-87. [PMID: 30076502 DOI: 10.1007/s10439-018-2107-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
80 Cybulska M, Olesinski T, Goryca K, Paczkowska K, Statkiewicz M, Kopczynski M, Grochowska A, Unrug-Bielawska K, Tyl-Bielicka A, Gajewska M, Mroz A, Dabrowska M, Karczmarski J, Paziewska A, Zając L, Bednarczyk M, Mikula M, Ostrowski J. Challenges in Stratifying the Molecular Variability of Patient-Derived Colon Tumor Xenografts. Biomed Res Int 2018;2018:2954208. [PMID: 30662905 DOI: 10.1155/2018/2954208] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
81 Sun J, Min YQ, Li Y, Sun X, Deng F, Wang H, Ning YJ. Animal Model of Severe Fever With Thrombocytopenia Syndrome Virus Infection. Front Microbiol 2021;12:797189. [PMID: 35087498 DOI: 10.3389/fmicb.2021.797189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Shih HP, Zhang X, Aronov AM. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nat Rev Drug Discov 2018;17:19-33. [PMID: 29075002 DOI: 10.1038/nrd.2017.194] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 12.6] [Reference Citation Analysis]
83 Ding S, Li S, Zhang S, Li Y. Genetic Alterations and Checkpoint Expression: Mechanisms and Models for Drug Discovery. Adv Exp Med Biol 2020;1248:227-50. [PMID: 32185713 DOI: 10.1007/978-981-15-3266-5_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
84 Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. Immunol Rev. 2017;280:249-279. [PMID: 29027221 DOI: 10.1111/imr.12573] [Cited by in Crossref: 84] [Cited by in F6Publishing: 89] [Article Influence: 21.0] [Reference Citation Analysis]
85 Cadilha BL, Benmebarek MR, Dorman K, Oner A, Lorenzini T, Obeck H, Vänttinen M, Di Pilato M, Pruessmann JN, Stoiber S, Huynh D, Märkl F, Seifert M, Manske K, Suarez-Gosalvez J, Zeng Y, Lesch S, Karches CH, Heise C, Gottschlich A, Thomas M, Marr C, Zhang J, Pandey D, Feuchtinger T, Subklewe M, Mempel TR, Endres S, Kobold S. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Sci Adv 2021;7:eabi5781. [PMID: 34108220 DOI: 10.1126/sciadv.abi5781] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Beola L, Gutiérrez L, Grazú V, Asín L. A Roadmap to the Standardization of In Vivo Magnetic Hyperthermia. Nanomaterials for Magnetic and Optical Hyperthermia Applications. Elsevier; 2019. pp. 317-37. [DOI: 10.1016/b978-0-12-813928-8.00012-0] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
87 Xiong D, Pan J, Yin Y, Jiang H, Szabo E, Lubet RA, Wang Y, You M. Novel mutational landscapes and expression signatures of lung squamous cell carcinoma. Oncotarget 2018;9:7424-41. [PMID: 29484121 DOI: 10.18632/oncotarget.23716] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
88 Bhinder B, Elemento O. Towards a better cancer precision medicine: systems biology meets immunotherapy. Curr Opin Syst Biol 2017;2:67-73. [PMID: 28989987 DOI: 10.1016/j.coisb.2017.01.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
89 Pan B, Wei X, Xu X. Patient-derived xenograft models in hepatopancreatobiliary cancer. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02454-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Trimaglio G, Tilkin-Mariamé AF, Feliu V, Lauzéral-Vizcaino F, Tosolini M, Valle C, Ayyoub M, Neyrolles O, Vergnolle N, Rombouts Y, Devaud C. Colon-specific immune microenvironment regulates cancer progression versus rejection. Oncoimmunology 2020;9:1790125. [PMID: 32923152 DOI: 10.1080/2162402X.2020.1790125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
91 Correia C, Weiskittel TM, Ung CY, Villasboas Bisneto JC, Billadeau DD, Kaufmann SH, Li H. Uncovering Pharmacological Opportunities for Cancer Stem Cells—A Systems Biology View. Front Cell Dev Biol 2022;10:752326. [DOI: 10.3389/fcell.2022.752326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Yang R, Wang Z, Yuan Y, Qian T, Zhou Q. cRGD target liposome delivery system promoted immunogenic cell death through enhanced anticancer potency of a thymidine conjugate under UVA activation as a cancer vaccine. European Journal of Medicinal Chemistry 2019;167:499-509. [DOI: 10.1016/j.ejmech.2019.02.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
93 Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, Villacorta-Martin C, Singhi AD, Moghe A, von Felden J, Tal Grinspan L, Wang S, Kamphorst AO, Monga SP, Brown BD, Villanueva A, Llovet JM, Merad M, Lujambio A. β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discov 2019;9:1124-41. [PMID: 31186238 DOI: 10.1158/2159-8290.CD-19-0074] [Cited by in Crossref: 123] [Cited by in F6Publishing: 103] [Article Influence: 41.0] [Reference Citation Analysis]
94 Pénzváltó Z, Chen JQ, Tepper CG, Davis RR, Silvestrini MT, Umeh-Garcia M, Sweeney C, Borowsky AD. A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy Trials. J Mammary Gland Biol Neoplasia 2019;24:149-62. [PMID: 30810966 DOI: 10.1007/s10911-019-09425-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
95 Li W, Deng Y, Chu Q, Zhang P. Gut microbiome and cancer immunotherapy. Cancer Lett. 2019;447:41-47. [PMID: 30684593 DOI: 10.1016/j.canlet.2019.01.015] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 15.0] [Reference Citation Analysis]
96 Si X, Xiao L, Brown CE, Wang D. Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models. Int J Mol Sci 2022;23:3154. [PMID: 35328572 DOI: 10.3390/ijms23063154] [Reference Citation Analysis]
97 Brighi C, Salimova E, de Veer M, Puttick S, Egan G. Translation of focused ultrasound for blood-brain barrier opening in glioma. J Control Release 2022;345:443-63. [PMID: 35337938 DOI: 10.1016/j.jconrel.2022.03.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
98 Ponzetta A, Mantovani A, Jaillon S. Dissecting neutrophil complexity in cancer. Emerg Top Life Sci 2017;1:457-70. [PMID: 33525797 DOI: 10.1042/ETLS20170062] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
99 Zhao Y, Shuen TWH, Toh TB, Chan XY, Liu M, Tan SY, Fan Y, Yang H, Lyer SG, Bonney GK, Loh E, Chang KTE, Tan TC, Zhai W, Chan JKY, Chow EK, Chee CE, Lee GH, Dan YY, Chow PK, Toh HC, Lim SG, Chen Q. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut 2018;67:1845-54. [PMID: 29602780 DOI: 10.1136/gutjnl-2017-315201] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 19.5] [Reference Citation Analysis]
100 Hong E, Dobrovolskaia MA. Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics. Adv Drug Deliv Rev 2019;141:3-22. [PMID: 29339144 DOI: 10.1016/j.addr.2018.01.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
101 Lévesque S, Le Naour J, Pietrocola F, Paillet J, Kremer M, Castoldi F, Baracco EE, Wang Y, Vacchelli E, Stoll G, Jolly A, De La Grange P, Zitvogel L, Kroemer G, Pol JG. A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. Oncoimmunology 2019;8:e1657375. [PMID: 31646107 DOI: 10.1080/2162402X.2019.1657375] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 9.7] [Reference Citation Analysis]
102 Xu YXZ, Mishra S. Obesity-Linked Cancers: Current Knowledge, Challenges and Limitations in Mechanistic Studies and Rodent Models. Cancers (Basel) 2018;10:E523. [PMID: 30567335 DOI: 10.3390/cancers10120523] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
103 Kapp K, Volz B, Oswald D, Wittig B, Baumann M, Schmidt M. Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors. Oncoimmunology 2019;8:e1659096. [PMID: 31741757 DOI: 10.1080/2162402X.2019.1659096] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
104 Poggi A, Villa F, Fernadez JLC, Costa D, Zocchi MR, Benelli R. Three-Dimensional Culture Models to Study Innate Anti-Tumor Immune Response: Advantages and Disadvantages. Cancers (Basel) 2021;13:3417. [PMID: 34298630 DOI: 10.3390/cancers13143417] [Reference Citation Analysis]
105 Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 2018;8:196-215. [PMID: 29101162 DOI: 10.1158/2159-8290.CD-17-0833] [Cited by in Crossref: 174] [Cited by in F6Publishing: 113] [Article Influence: 34.8] [Reference Citation Analysis]
106 Budhwani KI, Patel ZH, Guenter RE, Charania AA. A hitchhiker’s guide to cancer models. Trends in Biotechnology 2022. [DOI: 10.1016/j.tibtech.2022.04.003] [Reference Citation Analysis]
107 Peters S, Paz-Ares L, Herbst RS, Reck M. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects. J Immunother Cancer 2022;10:e004863. [PMID: 35858709 DOI: 10.1136/jitc-2022-004863] [Reference Citation Analysis]
108 Saito R, Kobayashi T, Kashima S, Matsumoto K, Ogawa O. Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology. Int J Clin Oncol 2020;25:831-41. [PMID: 31407168 DOI: 10.1007/s10147-019-01520-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
109 Jenkins RW, Fisher DE. Treatment of Advanced Melanoma in 2020 and Beyond. J Invest Dermatol 2021;141:23-31. [PMID: 32268150 DOI: 10.1016/j.jid.2020.03.943] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 17.0] [Reference Citation Analysis]
110 Orecchioni S, Talarico G, Labanca V, Calleri A, Mancuso P, Bertolini F. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. Br J Cancer 2018;118:1329-36. [PMID: 29695766 DOI: 10.1038/s41416-018-0076-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
111 Griffiths GL, Vasquez C, Escorcia F, Clanton J, Lindenberg L, Mena E, Choyke PL. Translating a radiolabeled imaging agent to the clinic. Adv Drug Deliv Rev 2022;181:114086. [PMID: 34942275 DOI: 10.1016/j.addr.2021.114086] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 de Leve S, Wirsdörfer F, Jendrossek V. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy. Front Immunol 2019;10:698. [PMID: 31024543 DOI: 10.3389/fimmu.2019.00698] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
113 Cho K, Ro SW, Seo SH, Jeon Y, Moon H, Kim DY, Kim SU. Genetically Engineered Mouse Models for Liver Cancer. Cancers (Basel) 2019;12:E14. [PMID: 31861541 DOI: 10.3390/cancers12010014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
114 Helmlinger G, Sokolov V, Peskov K, Hallow KM, Kosinsky Y, Voronova V, Chu L, Yakovleva T, Azarov I, Kaschek D, Dolgun A, Schmidt H, Boulton DW, Penland RC. Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development. CPT Pharmacometrics Syst Pharmacol 2019;8:380-95. [PMID: 31087533 DOI: 10.1002/psp4.12426] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
115 Lampreht Tratar U, Horvat S, Cemazar M. Transgenic Mouse Models in Cancer Research. Front Oncol 2018;8:268. [PMID: 30079312 DOI: 10.3389/fonc.2018.00268] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 13.5] [Reference Citation Analysis]
116 Galassi C, Manic G, Musella M, Sistigu A, Vitale I. Assessment of IFN-γ and granzyme-B production by in "sitro" technology. Methods Enzymol 2020;631:391-414. [PMID: 31948559 DOI: 10.1016/bs.mie.2019.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
117 Lee SK, Park MJ, Choi JW, Baek JA, Kim SY, Choi HJ, You YK, Jang JW, Sung PS, Bae SH, Yoon SK, Choi JY, Cho ML. Patient-Derived Avatar Mouse Model to Predict the Liver Immune Homeostasis of Long-Term Stable Liver Transplant Patients. Front Immunol 2022;13:817006. [PMID: 35418987 DOI: 10.3389/fimmu.2022.817006] [Reference Citation Analysis]
118 Tian H, Lyu Y, Yang YG, Hu Z. Humanized Rodent Models for Cancer Research. Front Oncol 2020;10:1696. [PMID: 33042811 DOI: 10.3389/fonc.2020.01696] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
119 Altorki NK, Markowitz GJ, Gao D, Port JL, Saxena A, Stiles B, McGraw T, Mittal V. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer 2019;19:9-31. [PMID: 30532012 DOI: 10.1038/s41568-018-0081-9] [Cited by in Crossref: 225] [Cited by in F6Publishing: 238] [Article Influence: 75.0] [Reference Citation Analysis]
120 Overgaard NH, Fan TM, Schachtschneider KM, Principe DR, Schook LB, Jungersen G. Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research. ILAR J 2018;59:247-62. [PMID: 30476148 DOI: 10.1093/ilar/ily014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
121 Clohessy JG, Pandolfi PP. The Mouse Hospital and Its Integration in Ultra-Precision Approaches to Cancer Care. Front Oncol 2018;8:340. [PMID: 30211119 DOI: 10.3389/fonc.2018.00340] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
122 Richards JR, Yoo JH, Shin D, Odelberg SJ. Mouse models of uveal melanoma: Strengths, weaknesses, and future directions. Pigment Cell Melanoma Res 2020;33:264-78. [PMID: 31880399 DOI: 10.1111/pcmr.12853] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
123 Memon H, Patel BM. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view. Life Sciences 2019;233:116713. [DOI: 10.1016/j.lfs.2019.116713] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
124 Gross ET, Han S, Vemu P, Peinado CD, Marsala M, Ellies LG, Bui JD. Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis. Oncoimmunology 2017;6:e1268310. [PMID: 28344881 DOI: 10.1080/2162402X.2016.1268310] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
125 Yu CI, Marches F, Wu T, Martinek J, Palucka K. Techniques for the generation of humanized mouse models for immuno-oncology. Tumor Immunology and Immunotherapy – Integrated Methods Part B. Elsevier; 2020. pp. 351-68. [DOI: 10.1016/bs.mie.2019.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
126 Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity 2020;52:17-35. [PMID: 31940268 DOI: 10.1016/j.immuni.2019.12.011] [Cited by in Crossref: 264] [Cited by in F6Publishing: 248] [Article Influence: 132.0] [Reference Citation Analysis]
127 Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev 2018;32:1105-40. [PMID: 30181359 DOI: 10.1101/gad.315739.118] [Cited by in Crossref: 110] [Cited by in F6Publishing: 106] [Article Influence: 27.5] [Reference Citation Analysis]
128 Onaciu A, Munteanu R, Munteanu VC, Gulei D, Raduly L, Feder RI, Pirlog R, Atanasov AG, Korban SS, Irimie A, Berindan-Neagoe I. Spontaneous and Induced Animal Models for Cancer Research. Diagnostics (Basel) 2020;10:E660. [PMID: 32878340 DOI: 10.3390/diagnostics10090660] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
129 Powley IR, Patel M, Miles G, Pringle H, Howells L, Thomas A, Kettleborough C, Bryans J, Hammonds T, MacFarlane M, Pritchard C. Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery. Br J Cancer 2020;122:735-44. [PMID: 31894140 DOI: 10.1038/s41416-019-0672-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 18.0] [Reference Citation Analysis]
130 Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE, Gilham DE. CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity. Mol Ther Oncolytics 2018;8:41-51. [PMID: 29367945 DOI: 10.1016/j.omto.2017.12.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 9.4] [Reference Citation Analysis]
131 De Giovanni C, Nicoletti G, Landuzzi L, Palladini A, Lollini PL, Nanni P. Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model. Cancers (Basel) 2019;11:E1889. [PMID: 31783695 DOI: 10.3390/cancers11121889] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
132 Buqué A, Perez-Lanzón M, Petroni G, Humeau J, Bloy N, Yamazaki T, Sato A, Kroemer G, Galluzzi L. MPA/DMBA-driven mammary carcinomas. Methods Cell Biol 2021;163:1-19. [PMID: 33785159 DOI: 10.1016/bs.mcb.2020.08.003] [Reference Citation Analysis]
133 Sosnowska A, Chlebowska-Tuz J, Matryba P, Pilch Z, Greig A, Wolny A, Grzywa TM, Rydzynska Z, Sokolowska O, Rygiel TP, Grzybowski M, Stanczak P, Blaszczyk R, Nowis D, Golab J. Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma. Oncoimmunology 2021;10:1956143. [PMID: 34367736 DOI: 10.1080/2162402X.2021.1956143] [Reference Citation Analysis]
134 Rossi M, Botta C, Arbitrio M, Grembiale RD, Tagliaferri P, Tassone P. Mouse models of multiple myeloma: technologic platforms and perspectives. Oncotarget 2018;9:20119-33. [PMID: 29732008 DOI: 10.18632/oncotarget.24614] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
135 Graveline R, Haida M, Dumont C, Poulin D, Poitout-Belissent F, Samadfam R, Kronenberg S, Regenass-Lechner F, Prell R, Piche MS. Development of a nonhuman primate challenge model to evaluate CD8+ T cell responses to an adenovirus-based vaccine expressing SIV proteins upon repeat-dose treatment with checkpoint inhibitors. MAbs 2022;14:1979447. [PMID: 34923919 DOI: 10.1080/19420862.2021.1979447] [Reference Citation Analysis]
136 Nishida-Aoki N, Gujral TS. Emerging approaches to study cell-cell interactions in tumor microenvironment. Oncotarget 2019;10:785-97. [PMID: 30774780 DOI: 10.18632/oncotarget.26585] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
137 Liao HW, Hung MC. Intracaecal Orthotopic Colorectal Cancer Xenograft Mouse Model. Bio Protoc 2017;7:e2311. [PMID: 29104894 DOI: 10.21769/BioProtoc.2311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
138 Liu S, Huang F, Ru G, Wang Y, Zhang B, Chen X, Chu L. Mouse Models of Hepatocellular Carcinoma: Classification, Advancement, and Application. Front Oncol 2022;12:902820. [DOI: 10.3389/fonc.2022.902820] [Reference Citation Analysis]
139 Morton JJ, Keysar SB, Perrenoud L, Chimed TS, Reisinger J, Jackson B, Le PN, Nieto C, Gomez K, Miller B, Gao D, Somerset H, Wang XJ, Jimeno A. Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer. Mol Carcinog 2018;57:1651-63. [PMID: 30129680 DOI: 10.1002/mc.22887] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
140 Yi M, Yu S, Qin S, Liu Q, Xu H, Zhao W, Chu Q, Wu K. Gut microbiome modulates efficacy of immune checkpoint inhibitors. J Hematol Oncol. 2018;11:47. [PMID: 29580257 DOI: 10.1186/s13045-018-0592-6] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 16.3] [Reference Citation Analysis]
141 Ireson CR, Alavijeh MS, Palmer AM, Fowler ER, Jones HJ. The role of mouse tumour models in the discovery and development of anticancer drugs. Br J Cancer 2019;121:101-8. [PMID: 31231121 DOI: 10.1038/s41416-019-0495-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
142 Carlson PM, Mohan M, Rodriguez M, Subbotin V, Sun CX, Patel RB, Birstler J, Hank JA, Rakhmilevich AL, Morris ZS, Erbe AK, Sondel PM. Depth of tumor implantation affects response to in situ vaccination in a syngeneic murine melanoma model. J Immunother Cancer 2021;9:e002107. [PMID: 33858849 DOI: 10.1136/jitc-2020-002107] [Reference Citation Analysis]
143 Galluzzi L, Kroemer G. Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate. Oncoimmunology 2018;7:e1528815. [PMID: 30524910 DOI: 10.1080/2162402X.2018.1528815] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
144 Waaijer SJH, Warnders FJ, Stienen S, Friedrich M, Sternjak A, Cheung HK, van Scheltinga AGTT, Schröder CP, de Vries EGE, Lub-de Hooge MN. Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors. Clin Cancer Res 2018;24:4988-96. [PMID: 29980531 DOI: 10.1158/1078-0432.CCR-18-0786] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
145 Migliorini D, Mason NJ, Posey AD. Keeping the Engine Running: The Relevance and Predictive Value of Preclinical Models for CAR-T Cell Development. ILAR J 2018;59:276-85. [PMID: 31095687 DOI: 10.1093/ilar/ilz009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
146 Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer 2018;118:9-16. [PMID: 29319049 DOI: 10.1038/bjc.2017.434] [Cited by in Crossref: 444] [Cited by in F6Publishing: 431] [Article Influence: 111.0] [Reference Citation Analysis]
147 Magiera-Mularz K, Kocik J, Musielak B, Plewka J, Sala D, Machula M, Grudnik P, Hajduk M, Czepiel M, Siedlar M, Holak TA, Skalniak L. Human and mouse PD-L1: similar molecular structure, but different druggability profiles. iScience 2021;24:101960. [PMID: 33437940 DOI: 10.1016/j.isci.2020.101960] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
148 Inamura K. Roles of microbiota in response to cancer immunotherapy. Semin Cancer Biol 2020;65:164-75. [PMID: 31911189 DOI: 10.1016/j.semcancer.2019.12.026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
149 Philip M, Schietinger A. CD8+ T cell differentiation and dysfunction in cancer. Nat Rev Immunol 2021. [PMID: 34253904 DOI: 10.1038/s41577-021-00574-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
150 Vatner R, James CD, Sathiaseelan V, Bondra KM, Kalapurakal JA, Houghton PJ. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges. Pediatr Blood Cancer 2021;68 Suppl 2:e28439. [PMID: 32827353 DOI: 10.1002/pbc.28439] [Reference Citation Analysis]
151 Enot DP, Vacchelli E, Jacquelot N, Zitvogel L, Kroemer G. TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves. Oncoimmunology 2018;7:e1462431. [PMID: 30228932 DOI: 10.1080/2162402X.2018.1462431] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 10.5] [Reference Citation Analysis]
152 Lin L, Wang Y, Cai M, Jiang X, Hu Y, Dong Z, Yin D, Liu Y, Yang S, Liu Z, Zhuang J, Xu Y, Guo CF, Chang L. Multimicrochannel Microneedle Microporation Platform for Enhanced Intracellular Drug Delivery. Adv Funct Materials 2022;32:2109187. [DOI: 10.1002/adfm.202109187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
153 Johnsen JI, Dyberg C, Fransson S, Wickström M. Molecular mechanisms and therapeutic targets in neuroblastoma. Pharmacol Res 2018;131:164-76. [PMID: 29466695 DOI: 10.1016/j.phrs.2018.02.023] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
154 Fiori ME, Villanova L, De Maria R. Cancer stem cells: at the forefront of personalized medicine and immunotherapy. Current Opinion in Pharmacology 2017;35:1-11. [DOI: 10.1016/j.coph.2017.04.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
155 Lenting K, Verhaak R, Ter Laan M, Wesseling P, Leenders W. Glioma: experimental models and reality. Acta Neuropathol 2017;133:263-82. [PMID: 28074274 DOI: 10.1007/s00401-017-1671-4] [Cited by in Crossref: 155] [Cited by in F6Publishing: 134] [Article Influence: 31.0] [Reference Citation Analysis]
156 Dutta D, Lim SH. Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions. Biomark Res. 2020;8:31. [PMID: 32817793 DOI: 10.1186/s40364-020-00211-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
157 Li HD, Cuevas I, Zhang M, Lu C, Alam MM, Fu YX, You MJ, Akbay EA, Zhang H, Castrillon DH. Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load. J Clin Invest 2018;128:4179-91. [PMID: 30124468 DOI: 10.1172/JCI122095] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
158 Li E, Lin L, Chen CW, Ou DL. Mouse Models for Immunotherapy in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1800. [PMID: 31731753 DOI: 10.3390/cancers11111800] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
159 Oshima Y, Sano M, Kajiwara I, Ichimaru Y, Itaya T, Kuramochi T, Hayashi E, Kim J, Kitajima O, Masugi Y, Masamune A, Ijichi H, Ishii Y, Suzuki T. Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma. Br J Anaesth 2022:S0007-0912(21)00873-4. [PMID: 35120712 DOI: 10.1016/j.bja.2021.12.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
160 Kötzner L, Huck B, Garg S, Urbahns K. Small molecules-Giant leaps for immuno-oncology. Prog Med Chem 2020;59:1-62. [PMID: 32362326 DOI: 10.1016/bs.pmch.2019.11.001] [Reference Citation Analysis]
161 Zhao X, Wang X, Feng Y, Agrawal S, Shah DK. Application of PK-PD Modeling and Simulation Approaches for Immuno-Oncology Drugs. In: Tabrizi MA, Bornstein GG, Klakamp SL, editors. Development of Antibody-Based Therapeutics. Singapore: Springer; 2018. pp. 207-22. [DOI: 10.1007/978-981-13-0496-5_11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
162 Lopes N, Correia VG, Palma AS, Brito C. Cracking the Breast Cancer Glyco-Code through Glycan-Lectin Interactions: Targeting Immunosuppressive Macrophages. Int J Mol Sci 2021;22:1972. [PMID: 33671245 DOI: 10.3390/ijms22041972] [Reference Citation Analysis]
163 Buqué A, Galluzzi L. Modeling Tumor Immunology and Immunotherapy in Mice. Trends Cancer 2018;4:599-601. [PMID: 30149876 DOI: 10.1016/j.trecan.2018.07.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 9.5] [Reference Citation Analysis]
164 Inamura K. Gut microbiota contributes towards immunomodulation against cancer: New frontiers in precision cancer therapeutics. Semin Cancer Biol 2021;70:11-23. [PMID: 32580023 DOI: 10.1016/j.semcancer.2020.06.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
165 Yanguas-Casás N, Pedrosa L, Fernández-Miranda I, Sánchez-Beato M. An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach. Cancers (Basel) 2021;13:2893. [PMID: 34207773 DOI: 10.3390/cancers13122893] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 Buqué A, Galluzzi L. Preface: Chemical carcinogenesis in mice as a model of human cancer: Pros and cons. Methods Cell Biol 2021;163:xvii-xxv. [PMID: 33785172 DOI: 10.1016/S0091-679X(21)00040-6] [Reference Citation Analysis]
167 Halbritter F, Farlik M, Schwentner R, Jug G, Fortelny N, Schnöller T, Pisa H, Schuster LC, Reinprecht A, Czech T, Gojo J, Holter W, Minkov M, Bauer WM, Simonitsch-Klupp I, Bock C, Hutter C. Epigenomics and Single-Cell Sequencing Define a Developmental Hierarchy in Langerhans Cell Histiocytosis. Cancer Discov 2019;9:1406-21. [PMID: 31345789 DOI: 10.1158/2159-8290.CD-19-0138] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
168 Homicsko K. Organoid technology and applications in cancer immunotherapy and precision medicine. Curr Opin Biotechnol 2020;65:242-7. [PMID: 32603978 DOI: 10.1016/j.copbio.2020.05.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
169 Carter LM, Poty S, Sharma SK, Lewis JS. Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection. J Labelled Comp Radiopharm 2018;61:611-35. [PMID: 29412489 DOI: 10.1002/jlcr.3612] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
170 Hachey SJ, Hughes CCW. Applications of tumor chip technology. Lab Chip 2018;18:2893-912. [PMID: 30156248 DOI: 10.1039/c8lc00330k] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 15.0] [Reference Citation Analysis]
171 Noble JN, Mishra A. Development and Significance of Mouse Models in Lymphoma Research. Curr Hematol Malig Rep 2019;14:119-26. [PMID: 30848424 DOI: 10.1007/s11899-019-00504-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
172 Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, Karin M, Kaufman HL, Kepp O, Kroemer G, Lasarte JJ, Loi S, Lotze MT, Manic G, Merghoub T, Melcher AA, Mossman KL, Prosper F, Rekdal Ø, Rescigno M, Riganti C, Sistigu A, Smyth MJ, Spisek R, Stagg J, Strauss BE, Tang D, Tatsuno K, van Gool SW, Vandenabeele P, Yamazaki T, Zamarin D, Zitvogel L, Cesano A, Marincola FM. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer 2020;8:e000337. [PMID: 32209603 DOI: 10.1136/jitc-2019-000337] [Cited by in Crossref: 131] [Cited by in F6Publishing: 143] [Article Influence: 131.0] [Reference Citation Analysis]